Akero Therapeutics (AKRO) Competitors $51.41 -1.95 (-3.65%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$51.88 +0.47 (+0.90%) As of 09:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AKRO vs. SMMT, ITCI, GMAB, RDY, ASND, VTRS, QGEN, MRNA, BPMC, and VRNAShould you be buying Akero Therapeutics stock or one of its competitors? The main competitors of Akero Therapeutics include Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), Moderna (MRNA), Blueprint Medicines (BPMC), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "pharmaceutical products" industry. Akero Therapeutics vs. Its Competitors Summit Therapeutics Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Ascendis Pharma A/S Viatris Qiagen Moderna Blueprint Medicines Verona Pharma PLC American Depositary Share Summit Therapeutics (NASDAQ:SMMT) and Akero Therapeutics (NASDAQ:AKRO) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends. Which has stronger earnings & valuation, SMMT or AKRO? Summit Therapeutics has higher revenue and earnings than Akero Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Akero Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSummit Therapeutics$700K22,492.29-$221.32M-$0.34-62.35Akero TherapeuticsN/AN/A-$252.06M-$1.95-26.36 Which has more volatility & risk, SMMT or AKRO? Summit Therapeutics has a beta of -1.02, meaning that its stock price is 202% less volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of -0.15, meaning that its stock price is 115% less volatile than the S&P 500. Do analysts prefer SMMT or AKRO? Summit Therapeutics presently has a consensus target price of $34.67, suggesting a potential upside of 63.52%. Akero Therapeutics has a consensus target price of $82.50, suggesting a potential upside of 60.47%. Given Summit Therapeutics' higher probable upside, research analysts plainly believe Summit Therapeutics is more favorable than Akero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Summit Therapeutics 2 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.79Akero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders have more ownership in SMMT or AKRO? 4.6% of Summit Therapeutics shares are owned by institutional investors. 84.9% of Summit Therapeutics shares are owned by company insiders. Comparatively, 7.1% of Akero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is SMMT or AKRO more profitable? Akero Therapeutics' return on equity of -15.19% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Summit TherapeuticsN/A -62.87% -51.61% Akero Therapeutics N/A -15.19%-13.97% Does the media favor SMMT or AKRO? In the previous week, Summit Therapeutics had 12 more articles in the media than Akero Therapeutics. MarketBeat recorded 14 mentions for Summit Therapeutics and 2 mentions for Akero Therapeutics. Summit Therapeutics' average media sentiment score of 0.75 beat Akero Therapeutics' score of 0.62 indicating that Summit Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Akero Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummarySummit Therapeutics beats Akero Therapeutics on 10 of the 15 factors compared between the two stocks. Get Akero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AKRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKRO vs. The Competition Export to ExcelMetricAkero TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.25B$2.85B$5.48B$8.94BDividend YieldN/A2.69%5.38%4.12%P/E Ratio-26.3621.1726.2219.74Price / SalesN/A262.85394.92109.12Price / CashN/A41.8936.4957.06Price / Book4.787.237.915.37Net Income-$252.06M-$55.05M$3.15B$248.34M7 Day Performance-6.60%-0.60%0.75%1.67%1 Month Performance1.34%3.77%3.46%4.56%1 Year Performance129.71%2.20%34.60%18.42% Akero Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKROAkero Therapeutics3.5685 of 5 stars$51.41-3.7%$82.50+60.5%+122.0%$4.25BN/A-26.3630SMMTSummit Therapeutics2.6319 of 5 stars$20.39-0.8%$35.09+72.1%+160.4%$15.27B$700K-59.97110Analyst UpgradeITCIIntra-Cellular Therapies0.9104 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.8921 of 5 stars$20.68-2.3%$39.17+89.4%-16.5%$13.57B$3.12B11.752,682High Trading VolumeRDYDr. Reddy's Laboratories3.0164 of 5 stars$15.31+0.5%$16.95+10.7%-1.0%$12.71B$3.81B23.2027,811Positive NewsASNDAscendis Pharma A/S3.5208 of 5 stars$175.78-0.6%$220.67+25.5%+28.4%$10.81B$393.54M-27.991,017Positive NewsVTRSViatris3.0314 of 5 stars$8.85-0.2%$10.40+17.5%-13.3%$10.41B$14.74B-2.7932,000QGENQiagen3.7472 of 5 stars$46.72-0.1%$47.74+2.2%+23.2%$10.39B$1.98B117.145,765Dividend AnnouncementMRNAModerna4.3639 of 5 stars$25.67-0.9%$46.61+81.6%-75.3%$10.02B$3.24B-2.945,800BPMCBlueprint Medicines1.736 of 5 stars$128.40+0.2%$128.06-0.3%+17.5%$8.28B$508.82M-51.98640Positive NewsHigh Trading VolumeVRNAVerona Pharma PLC American Depositary Share2.57 of 5 stars$97.05+2.9%$101.10+4.2%+483.4%$8.03B$42.28M-48.5330Positive NewsAnalyst ForecastGap Up Related Companies and Tools Related Companies Summit Therapeutics Alternatives Intra-Cellular Therapies Alternatives Genmab A/S Alternatives Dr. Reddy's Laboratories Alternatives Ascendis Pharma A/S Alternatives Viatris Alternatives Qiagen Alternatives Moderna Alternatives Blueprint Medicines Alternatives Verona Pharma PLC American Depositary Share Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKRO) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AKRO Stock Alerts